Treatment
PCSA • Root Cause Medicine • 20-Minute Appointments
Drugs Are an Option, Not the Only Option
Long-Term Prescription Review • Cancer Research Reform
The Problem
A patient walks into a GP surgery. They have acid reflux. The GP has 10 minutes. In 10 minutes, you cannot take a full history, explore diet, assess lifestyle, discuss stress, examine the patient, and develop a treatment plan. You can write a prescription. So the GP writes a prescription. Omeprazole. The patient takes it. The reflux stops. The GP’s job is done.
Thirty years later, the patient has magnesium depletion, increased fracture risk, kidney problems, liver damage, and an elevated risk of C. difficile infection. All documented side effects of long-term omeprazole use. Nobody ever asked: what are you eating that causes the reflux? Could we remove the cause instead of suppressing the symptom? Could you stop eating the thing that makes your stomach produce excess acid, rather than taking a drug that stops your stomach producing acid at all — including the acid you need to digest food and absorb nutrients?
This is not the GP’s fault. The GP has 10 minutes. In 10 minutes, the prescription is the only option that fits the time slot. The system is designed around 10-minute consultations because 10-minute consultations process more patients per hour. The system is optimised for throughput, not for outcomes. The pharmaceutical industry profits from throughput. The patient pays the price.
BUILD will replace throughput medicine with root cause medicine. The framework is PCSA: Person, Cause, Symptoms, Action. The appointment is 20 minutes, not 10. The action is whatever actually fixes the problem — which may be a drug, but it may also be a diet change, a lifestyle adjustment, a referral for physiotherapy, a stress management programme, or simply the words ‘stop eating wheat and see if it helps.’ Pfizer will hate it. The patient will thank you.
The GP’s job is not to prescribe. It is to understand. Understand the person. Find the cause. Treat accordingly. Drugs are one tool. They are not the only tool. And they should not be the first tool reached for because the appointment is too short to think of anything else.
Pillar 1: PCSA — The Treatment Framework
PCAR in the justice system says: understand the person before you sentence them. PCSA in medicine says: understand the person before you prescribe them. Same philosophy. Different application.
1.1 — P: Person
Who is this patient? Not just their name, age, and the symptom they presented with. Who are they? What do they eat? How much do they move? What do they do for work? What stresses are they under? How do they sleep? What is their home environment? What is their family history? What medications are they already on? What has already been tried?
The Person assessment is the foundation. A 45-year-old office worker with acid reflux who eats fast food five days a week, drinks six coffees a day, and is under significant workplace stress is a different patient from a 45-year-old marathon runner with acid reflux who eats clean and sleeps eight hours. The symptom is identical. The person is not. The treatment should not be identical either.
1.2 — C: Cause
WHY does this patient have this condition? Not the diagnosis — the reason for the diagnosis. Acid reflux is not a cause. It is a symptom. The cause might be diet (acidic or fatty foods triggering excess acid production). It might be stress (cortisol increasing stomach acid). It might be a hiatal hernia (mechanical). It might be H. pylori infection (bacterial). It might be medication-induced (NSAIDs, aspirin). Each cause has a different treatment. Omeprazole treats none of them. It suppresses the symptom while the cause continues.
The GP investigates the cause before reaching for the prescription pad. This takes time. That is why the appointment is 20 minutes, not 10 (Pillar 2). The 10-minute appointment is why the cause is never investigated. The prescription is the shortcut that the time pressure demands. Remove the time pressure and the shortcut becomes unnecessary.
1.3 — S: Symptoms
What is the patient actually experiencing? Everything, not just the headline. A patient presents with acid reflux. The GP using PCSA asks: what else? Fatigue? Joint pain? Brain fog? Skin issues? Digestive problems beyond the reflux? Mood changes? Every symptom is logged. The pattern often reveals the cause. Acid reflux plus fatigue plus joint pain plus brain fog might point to a food intolerance that one drug will never fix but one dietary change might resolve entirely.
The current model treats each symptom separately: one drug for the reflux, one for the fatigue, one for the joint pain. Three drugs, three sets of side effects, three prescriptions to manage, and the underlying cause untouched. PCSA treats the pattern, finds the cause, and addresses it. If the cause is wheat intolerance, removing wheat fixes the reflux, the fatigue, the joint pain, and the brain fog. Zero drugs. Zero side effects. Zero cost.
1.4 — A: Action
What intervention actually fits? The action menu is wider than the prescription pad:
Dietary intervention — food elimination trials, nutritional assessment, referral to a dietitian. Lifestyle modification — exercise prescription (the leisure centres in the NHS Charter, Pillar 12, are the other half of this), sleep hygiene, stress management techniques. Physical therapy — physiotherapy, osteopathy, acupuncture for pain management (evidence-based for specific conditions). Herbal and natural medicine — where evidence supports efficacy for the specific condition. Psychological support — CBT, counselling, talking therapy for conditions with a psychological component. Monitoring and watchful waiting — not every symptom requires immediate intervention; some resolve with time and lifestyle adjustment. And pharmaceutical intervention — when the above have been explored and either failed or are inappropriate for the condition. Drugs remain a tool. An important tool. Sometimes the only tool. But the last tool reached for, not the first.
Pillar 2: 20-Minute Appointments
2.1 — The 10-Minute Trap
The standard GP appointment in England is 10 minutes. In 10 minutes, a GP can: listen to the symptom (2 minutes), check the computer (1 minute), examine the patient (3 minutes), write a prescription (2 minutes), and process the paperwork (2 minutes). There is no time to investigate the cause. There is no time to discuss lifestyle. There is no time to explore non-pharmaceutical options. There is no time to understand the person. There is time to prescribe and move on.
The 10-minute appointment exists because it maximises throughput. A GP seeing patients every 10 minutes processes 24 patients in a four-hour morning surgery. The same GP seeing patients every 20 minutes processes 12. The system values 24 prescriptions over 12 solutions.
2.2 — 20 Minutes Minimum
BUILD will mandate a minimum 20-minute GP appointment as the standard consultation length. Not an ‘extended’ appointment. Not a ‘complex case’ appointment. The standard. Every patient. Every time.
Twenty minutes allows the GP to conduct a PCSA assessment: understand the person (5 minutes), investigate the cause (5 minutes), catalogue the symptoms (3 minutes), discuss action options including non-pharmaceutical approaches (5 minutes), and agree a plan with the patient (2 minutes). The patient leaves with a plan, not just a prescription. The plan might include a prescription. It might not. But the decision is informed, not rushed.
2.3 — Fewer Appointments, Better Outcomes
The objection will be: fewer patients seen per day means longer waiting times. BUILD’s answer: fewer patients need to come back. A patient whose cause is identified and addressed in one 20-minute appointment does not return three more times with the same unresolved symptoms. A patient who is prescribed omeprazole in a 10-minute appointment returns when the omeprazole causes side effects, returns when the side effects need medication, and returns when the underlying cause — which was never investigated — worsens despite the symptom suppression.
Root cause medicine reduces repeat consultations. It reduces long-term prescribing. It reduces drug side effects. It reduces the secondary conditions caused by those side effects. It reduces hospital admissions. One proper appointment replaces three or four inadequate ones. The maths works.
Pillar 3: Long-Term Prescription Review
3.1 — Nobody Stays on a Drug for 30 Years Without Review
Every patient on a long-term prescription will receive a mandatory annual medication review. Not a repeat prescription rubber-stamped by a receptionist. A face-to-face review with a GP or pharmacist who examines: whether the patient still needs the drug; whether the original cause has been addressed (and if not, why not); whether the drug is causing secondary harm; whether a non-pharmaceutical alternative has become available or appropriate; and whether the dose is still correct.
A patient who has been on omeprazole for 15 years should have been reviewed 15 times. In practice, many long-term prescriptions are renewed automatically without any clinical review at all. The repeat prescription system — where the patient orders online and the prescription is issued without a consultation — is a conveyor belt that feeds patients to pharmaceutical companies indefinitely. BUILD will stop the conveyor belt.
3.2 — Polypharmacy Review
Patients on five or more concurrent medications — polypharmacy — will receive a specialist medication review to assess drug interactions, combined side effects, and whether any of the medications are treating side effects of the other medications. It is not uncommon for an elderly patient to be on 10–15 drugs, several of which exist solely to manage the side effects of the others. Drug A causes nausea. Drug B is prescribed for the nausea. Drug B causes insomnia. Drug C is prescribed for the insomnia. Drug C causes constipation. Drug D is prescribed for the constipation. Four drugs, one of which was needed. Three of which treat the consequences of the other.
A polypharmacy review strips the medication list back to what is genuinely necessary, eliminates cascade prescribing, and in many cases dramatically reduces the number of drugs the patient takes — improving their quality of life, reducing side effects, and cutting pharmaceutical costs.
Pillar 4: Cancer — Invest in Treatments That Don’t Destroy the Patient
4.1 — Beyond Chemotherapy
Chemotherapy was developed from mustard gas research in the 1940s. It works by poisoning the entire body and hoping the cancer cells — which divide faster than healthy cells — die first. It is brutal, debilitating, and in many cases life-shortening even when it is life-saving. A cancer patient who survives chemotherapy often lives with the long-term consequences — organ damage, immune suppression, secondary cancers, cognitive impairment — for the rest of their reduced life.
Chemotherapy has saved millions of lives. BUILD does not deny that. But it is a 1940s solution that we are still using in 2026 because the pharmaceutical industry has invested in refining the poison rather than replacing it. Refinement is profitable. Replacement is not, because a cure is a one-time sale and a treatment is a recurring revenue stream.
4.2 — Research Investment
BUILD will redirect cancer research funding toward treatments that attack the disease without destroying the patient: immunotherapy — training the patient’s own immune system to recognise and destroy cancer cells; targeted therapy — drugs that attack specific molecular targets on cancer cells without harming healthy tissue; precision medicine — treatments designed for the specific genetic profile of the patient’s tumour; gene therapy — correcting or replacing the genetic mutations that cause cancer; and early detection technology — blood tests, imaging, and biomarkers that identify cancer before it becomes advanced.
The objective is a future where cancer treatment means a course of targeted therapy with minimal side effects, not six months of systemic poisoning followed by years of recovery from the treatment. The science is already producing results. CAR-T cell therapy is curing blood cancers that were previously untreatable. Immunotherapy checkpoint inhibitors are producing durable responses in melanoma, lung cancer, and kidney cancer. The breakthroughs are happening. The investment needs to follow.
Pillar 5: Pharmaceutical Independence
5.1 — End the Revolving Door
The relationship between the pharmaceutical industry and the medical profession is too close. Drug companies fund research, sponsor conferences, pay for medical education, provide free samples, and employ representatives whose job is to persuade doctors to prescribe their products. The regulatory bodies that approve drugs include members with financial ties to the companies they regulate. This is not corruption in the traditional sense. It is structural capture — a system where the regulated industry funds, trains, and influences the people who are supposed to regulate it.
BUILD will sever the financial ties between pharmaceutical companies and prescribing clinicians. No drug company may fund GP education, sponsor medical conferences attended by prescribers, or provide gifts, samples, or hospitality to any clinician who prescribes their products. Medical education is funded by the state. Research is funded by the independent science board (Farming Charter, Pillar 8.2). Regulation is conducted by people who have never received a penny from the industry they regulate.
5.2 — Generic First, Brand Never
Where a generic equivalent exists, the generic is prescribed. Always. Not ‘where clinically appropriate’ — which leaves a loophole for brand-loyal prescribing — but always, unless the specific patient has a documented adverse reaction to the generic formulation. A generic statin is a statin. A generic omeprazole is omeprazole. The brand name is a marketing exercise, not a clinical distinction. The NHS stops paying for marketing.
The Medicine BUILD Will Deliver
These five pillars replace throughput medicine with root cause medicine. The GP sees the person, finds the cause, treats accordingly. Drugs are one option on a menu that includes diet, lifestyle, physiotherapy, herbal medicine, and psychological support. The appointment is 20 minutes because understanding a person takes longer than writing a prescription.
Nobody stays on a drug for 30 years without someone asking why. Polypharmacy is reviewed and stripped back. Cancer research investment goes to treatments that don’t destroy the patient. The pharmaceutical industry’s grip on prescribing is broken.
This will save lives. Not dramatically, not in a single headline, but steadily, patient by patient, as the system stops medicating symptoms and starts fixing causes. The patient who was going to spend 30 years on omeprazole stops eating the food that caused the reflux and never needs the drug. The patient who was going to take three drugs for side effects of one drug has the one drug reviewed and the other three stopped. The cancer patient receives immunotherapy instead of mustard gas.
The GP’s job is not to prescribe. It is to understand. PCSA: Person. Cause. Symptoms. Action. Understand the person. Find the cause. Map the symptoms. Choose the action — and the action does not have to be pharmaceutical. Pfizer will hate it. The patient will thank you.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BUILD UK
builduk.club
August 2026
Download this charter as a document (.docx) — the paper as written. What follows is the same text, readable.